the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

NASA cancels moon rover mission due to high costs and launch delays

WASHINGTON: US space agency NASA announced on Wednesday that it will not send its rover to the moon, citing high costs and launch delays as reasons for the cancellation, reported the German news agency (dpa).

The project, dubbed Volatiles Investigating Polar Exploration Rover or VIPER, will be discontinued following a “comprehensive internal review”, NASA said at a press conference.

The space agency said the decision to reconsider the project came amid escalating costs, potential future cost increases, and a launch date delay.

According to NASA, the rover was originally scheduled to launch in late 2023, but the launch had to be postponed to later this year.

After another delay, NASA had last anticipated that the launch would take place in September 2025.

The VIPER robot was poised to roam the moon’s south pole, gathering soil samples with a drill. The launch was planned to be carried out in collaboration with the private space company Astrobotic.

NASA said that the rover would now be dismantled and the parts used elsewhere.

“Our path forward will make maximum use of the technology and work that went into VIPER, while preserving critical funds to support our robust lunar portfolio,“ NASA manager Nicola Fox noted.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Addressing medical inflation

Consumers are struggling as medical insurance premiums surge, with over 340,000 dropping coverage amid calls for price regulation and stronger public healthcare

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings